S D Rubin - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Filters

S D Rubin

Showing results (1-10 of 3) with videos related to

Pageof 1

Sort By:

Cell Growth & Differentiation : the Molecular Biology Journal of the American Association for Cancer Research|April 1, 1993

Developmental expression of the vav protooncogeneX R Bustelo, S D Rubin, K L Suen, et al.

Inflammatory Bowel Diseases|September 19, 1998

Intravenous corticotrophin vs. hydrocortisone in the treatment of hospitalized patients with Crohn's disease: a randomized double-blind study and follow-upA Chun, R M Chadi, B I Korelitz, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 31, 2009

Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimensK L Blackwell, M D Pegram, E Tan-Chiu, et al.

Pageof 1

Search research articles

Showing results (1-10 of 3) with videos related to

Sort By:

Pageof 1

Cell Growth & Differentiation : the Molecular Biology Journal of the American Association for Cancer Research|April 1, 1993

Developmental expression of the vav protooncogeneX R Bustelo, S D Rubin, K L Suen, et al.

Inflammatory Bowel Diseases|September 19, 1998

Intravenous corticotrophin vs. hydrocortisone in the treatment of hospitalized patients with Crohn's disease: a randomized double-blind study and follow-upA Chun, R M Chadi, B I Korelitz, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 31, 2009

Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimensK L Blackwell, M D Pegram, E Tan-Chiu, et al.

Pageof 1